First report of Phase 3 ROBUST trial: R2-CHOP for frontline DLBCL

Is frontline R-CHOP still the standard of care for DLBCL?Подробнее

Can we improve on R-CHOP for the frontline treatment of DLBCL?Подробнее

3-year follow-up from the TRANSFORM trial: liso-cel is superior to SoC in R/R DLBCLПодробнее

PHOENIX: ibrutinib in combination with R-CHOP for DLBCLПодробнее

Dr. Vitolo on What the ROBUST Trial Data Means for ABC-Type DLBCПодробнее

Interpretation of R2-CHOP in large cell lymphomaПодробнее

Phase Ib trial of R-CHOP plus iberdomide or golcadomide in aggressive B-cell lymphomaПодробнее

Randomized R2-CHOP studies in DLBCLПодробнее

First-MIND: Phase Ib study of R-CHOP + tafasitamab ± lenalidomide in newly diagnosed DLCBLПодробнее

Insights into the ZUMA-23 trial: axi-cel in frontline high-risk LBCLПодробнее

POLARIX study: frontline therapy in DLBCLПодробнее

ROBUST study: why did it not meet its primary endpoint? A subgroup analysisПодробнее

Dr. Martin on Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCLПодробнее

Ibrutinib in DLBCL: revelations from further analysis of PHOENIXПодробнее

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCLПодробнее

Insights into the REMoDL-A trial: acalabrutinib plus R-CHOP for patients with DLBCLПодробнее

Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusionПодробнее

What are the Hurdles to Using Cell of Origin in Classification to Treat DLBCL?Подробнее

DLBCL Prognosis & Management in Front-line Settings #oncology #lungcancer #cancer #2023Подробнее